| [1] Stella B, Arpiceo S, Peracchia M T, et al. Design of folic acid-conjugated nanoparticles for drug targeting[J]. J Pharm Sci, 2000, 89(11): 1 452-1 464.[2] Zhang B, Li Y, Fang C Y, et al. Receptor-mediated cellular uptake of folate-conjugated fluorescent nanodiamonds: a combined ensemble and single-particle study[J]. Small, 2009, 5(22): 2 716-2 721.[3] Low P S, Antony A C. Folate receptor-targeted drugs for cancer and inflammatory diseases[J]. Adv Drug Deliv Rev, 2004, 56(8): 1 055-1 058.[4] Wang L, Li M, Zhang N. Folate-targeted docetaxel-lipid-based-nanosuspensions for active-targeted cancer therapy[J]. Int J Nanomedicine, 2012, 7: 3 281-3 294.[5] Muller B G, Leuenberger H, Kissel T. Albumin nanospheres as carriers for passive drug targeting: anoptimized manufacturing technique[J]. Pharm Res, 1996, 13(1): 32-37.[6] Wang Y X, Hussain S M, Krestin G P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging[J]. Eur Radiol, 2001, 11: 2 319-2 331.[7] Ak G, Sanlier S H. Synthesis of folate receptor-targeted and Doxorubicin-coupled chemotherapeutic nanoconjugate and research into its medical applications[J]. Prep Biochem Biotech, 2012, 42(6): 551-563.[8] Saxena V, Naguib Y, Hussain M D. Folate receptor targeted 17-allylamino-17-demethoxygeldanamycin (17-AAG) loaded polymeric nanoparticles for breast cancer[J]. Colloids Surf B Biointerfaces, 2012, 94: 274-280.[9] Wang H, Wang S, Liao Z, et al. Folate- targeting magnetic core-shell nanocarriers for selective drug release and imaging[J]. Int J Pharm, 2012, 430(1-2): 342-349.[10] Konda S D, Wang S, Brechbiel M, et al. Biodistdbution of a Gd-folatedendrimer, generation, in mice with folate-receptor positive andnegative ovarian tumor xenografts[J]. Invest Radiol, 2002, 37(4): 199-204. |
